Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Pramlintide acetate
Drug ID BADD_D01820
Description Pramlintide is a relatively new adjunct treatment for diabetes (both type 1 and 2), developed by Amylin Pharmaceuticals. It is derived from amylin, a hormone that is released into the bloodstream, in a similar pattern as insulin, after a meal. Like insulin, amylin is deficient in individuals with diabetes.
Indications and Usage For the treatment of type 1 and type 2 diabetes mellitus as an adjunct to preprandial insulin therapy in patients without adequate glycemic control of insulin therapy.
Marketing Status approved; investigational
ATC Code A10BX05
DrugBank ID DB01278
KEGG ID D05595
MeSH ID C105254
PubChem ID 16132446
TTD Drug ID D0C4AM
NDC Product Code 0310-6615; 0310-6627
UNII 726I6TE06G
Synonyms pramlintide | LYS-CYS-ASN-THR-ALA-THR-CYS-ALA-THR-GLN-ARG-LEU-ALA-ASN-PHE-LEU-VAL-HIS-SER-SER-ASN-ASN-PHE-GLY-PRO-ILE-LEU-PRO-PRO-THR-ASN-VAL-GLY-SER-ASN-THR-TYR-NH2 | Symlin | AC 0137 | AC 137 | pramlintide acetate | Tripro-Amylin
Chemical Information
Molecular Formula C171H269N51O53S2
CAS Registry Number 151126-32-8
SMILES CCC(C)C(C(=O)NC(CC(C)C)C(=O)N1CCCC1C(=O)N2CCCC2C(=O)NC(C(C)O)C(=O)NC(CC(=O)N)C(= O)NC(C(C)C)C(=O)NCC(=O)NC(CO)C(=O)NC(CC(=O)N)C(=O)NC(C(C)O)C(=O)NC(CC3=CC=C(C=C3 )O)C(=O)N)NC(=O)C4CCCN4C(=O)CNC(=O)C(CC5=CC=CC=C5)NC(=O)C(CC(=O)N)NC(=O)C(CC(=O) N)NC(=O)C(CO)NC(=O)C(CO)NC(=O)C(CC6=CN=CN6)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C( CC7=CC=CC=C7)NC(=O)C(CC(=O)N)NC(=O)C(C)NC(=O)C(CC(C)C)NC(=O)C(CCCNC(=N)N)NC(=O)C (CCC(=O)N)NC(=O)C(C(C)O)NC(=O)C(C)NC(=O)C(CS)NC(=O)C(C(C)O)NC(=O)C(C)NC(=O)C(C(C )O)NC(=O)C(CC(=O)N)NC(=O)C(CS)NC(=O)C(CCCCN)N
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice..
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Arthralgia15.01.02.001--
Dizziness17.02.05.003; 02.11.04.006; 24.06.02.007--
Fatigue08.01.01.002--
Hypersensitivity10.01.03.003--
Injection site reaction12.07.03.015; 08.02.03.014--
Injury12.01.08.004--Not Available
Nausea07.01.07.001--
Pancreatitis07.18.01.001--
Vomiting07.01.07.003--
Decreased appetite14.03.01.005; 08.01.09.028--
The 1th Page    1    Total 1 Pages